FDA — authorised 29 October 2007
- Application: NDA022068
- Marketing authorisation holder: NOVARTIS
- Status: supplemented
FDA authorised Tasigna on 29 October 2007
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 29 October 2007; FDA has authorised it.
NOVARTIS holds the US marketing authorisation.